Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Redcliffe Labs Announces Leadership Transition to Drive Healthcare Accessibility

Home
/
update
/
details

Labcorp Completes Acquisition of Select Invitae Assets

NextEdge Admin

05 Aug 2024

1 min 22 sec

Labcorp , a global leader in comprehensive laboratory services, has completed the acquisition of select assets from Invitae , a prominent medical genetics company. This merger aims to enhance patient care, clinician support, and pharmaceutical partnerships across therapy development, patient diagnosis, and personalized care.

"Labcorp and Invitae share a mission to leverage genetic insights to transform medicine, deliver personalized care, and improve health outcomes," stated Mark Schroeder, Executive Vice President and President of Diagnostics Laboratories and COO of Labcorp. By integrating Invitae's advanced science and experience, Labcorp will enhance its genetic testing solutions, particularly in oncology and rare diseases. This acquisition strengthens Labcorp's specialty testing capabilities and its use of genetic data to improve clinical trials and treatment strategies. The combined expertise will provide comprehensive patient insights, from testing and diagnosis to treatment, ultimately improving health outcomes.